Although the prevalence of ROS1-GOPC fusion is too low for a dedicated clinical investigation, research in NSCLC cell lines has demonstrated in-vitro inhibition of cell growth following exposure to crizotinib [21]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.